What is Universal Sequencing Technology?
Universal Sequencing Technology operates at the intersection of biotechnology and advanced data analytics, specializing in proprietary DNA sequencing solutions. The company is best known for its TELL-Seq Library Prep Kits and AmpliDrop Single Cell Kits, which effectively bridge the gap between short-read sequencing platforms and long-read performance. By enabling researchers to achieve high-fidelity genomic results without the prohibitive costs of traditional long-read systems, the firm has carved out a distinct competitive advantage. Their portfolio, which includes metagenomics applications and specialized grant programs, serves a diverse clientele of academic and commercial researchers focused on complex genomic discovery.
How much funding has Universal Sequencing Technology raised?
Universal Sequencing Technology has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Universal Sequencing Technology
PPP
Public-Private Partnership
What's next for Universal Sequencing Technology?
With this late-stage capital, Universal Sequencing Technology is expected to prioritize the scaling of its manufacturing capabilities and the global distribution of its TELL-Seq platform. The strategic roadmap likely involves expanding the reach of its single-cell sequencing services to meet the rising demand for precision medicine and microbial diagnostics. As the company transitions into this next phase of growth, the focus will shift toward establishing long-term partnerships with major sequencing hardware providers, thereby cementing its technology as an industry standard for cost-effective, high-resolution genomic analysis. The firm remains a key player to watch as it leverages this investment to drive innovation in the rapidly evolving life sciences landscape.
See full Universal Sequencing Technology company page
